
Conference Coverage
about 22 hours ago
Closing the Gap: How AON Turns AI and the Patient Voice Into PracticeLatest Content

Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment

Utilization of Social Determinants Z Codes and Health System Characteristics, 2015-2024

Dual-Eligible Enrollees Favor Switching MA Plans Over Leaving MA

FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion

VBC Risk Is Outpacing Provider Readiness, CMS Must Act

Shorts










Center on Health Equity & Access
All News

This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

OCT patterns help distinguish MS, NMOSD, and MOGAD after optic neuritis, while timing and protocol shape MRI's diagnostic yield, experts say.

Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.




























